TSHATaysha Gene Therapies, Inc.
Is it safe?
Forensics clean, with a caveat: a safe balance sheet, but heavy debt (BB) and big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$1.2M, 90 days to Oct 8, 2026), selling is often routine.
Net cash, but unprofitable, speculative. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -98% · now 36% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can TSHA take a bad year?
Taysha Gene Therapies, Inc. holds $406M more cash than debt, and is burning $33M a quarter, about 3.4 years of cover.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 8.22
Altman Z-score · safe zone, above 3
- Cash runway
- 3.4 years
Cash runway · burning $33M a quarter at the current rate
Details›
- Total debtQ2 2026
- $49M
- Cash and short-term investments
- $455M
- Net cash
- $406M
- EBITDA, trailing twelve months
- −$152M
- Operating profit, trailing twelve months
- −$153M
- Debt / equity
- 0.13×
- Annualised volatilitytwo years of daily moves
- 95%
- Worst drawdown on file
- −98%
- Below its 52-week high
- 36%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.